$BPMC

Blueprint Medicines Corp

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$44.61 ▼-0.624%

Extented Hours

VOLUME

173,508

DAY RANGE

44.15 - 45.17

52 WEEK

40.78 - 111.78

Join Discuss about BPMC with like-minded investors

profile
@dros #droscrew
recently

+Initiations 6/27: $ACM $AXTI $BLBX $CORT $DRI $ENOV $GROV $IFF $LQDT $ML $RPM $SIGI $TXRH . -Initiations 6/27: $ALB $BPMC $CE $EAT $LYB $ORCL

131 Replies 6 👍 12 🔥

profile
@dros #droscrew
recently

Upgrades 6/1: $BPMC $CTT $DHR $ENTA $FINV $FMX $HBCP $HTHT $LIN $NE $PK $VC $VRTX $XYL . Downgrades 6/1: $AOMR $CTT $DIBS $FTS $GDRX $GTES $KOF $LX $MDT $POSH $PTEN $SBSW $SEE $TPX $VLO

118 Replies 8 👍 15 🔥

profile
@dros #droscrew
recently

Downgrades 10/30: $APPS $BLCM $BPMC $CLBK $CXO $FITB $IPHI $NFE $NOK $NTCT $NUVA $PE $PRO $TEAM $YNDX

98 Replies 8 👍 7 🔥

Key Metrics

Market Cap

2.69 B

Beta

1.37

Avg. Volume

706.08 K

Shares Outstanding

59.83 M

Yield

0%

Public Float

0

Next Earnings Date

2023-02-15

Next Dividend Date

Company Information

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

CEO: Jeffrey Albers

Website:

HQ: 45 Sidney St Cambridge, 02139-4133 Massachusetts

Related News